Table 2.
Clinical trials of antagonists of the adenosinergic pathway
| Target | Drug | Clinical trial number | Cancer type | Combination partner | Study phase | References |
|---|---|---|---|---|---|---|
| CD73 | MEDI9447 | NCT02503774 | Solid tumors | Anti-PDL1 (MEDI4736) | Phase 1 | [25] |
| NCT03267589 | Ovarian cancer | Anti-PDL1 (durvalumab) | Phase 2 | [26] | ||
| CPI-006 | NCT03454451 | Advanced cancers | Anti-PDL1 (pembrolizumab) A2ARi(CPI-444) | Phase 1/1b | [27] | |
| A2AR | NIR178 | NCT03207867 | Solid tumors and non-Hodgkin lymphoma | Anti-PD1 (PDR001) | Phase 2 | [28] |
| PBF-509 | NCT02403193 | NSCLC | Anti-PD1 (PDR001) | Phase 1, phase 2 | [29] | |
| CPI-444 | NCT02655822 | Advanced cancers | Anti-PDL1 (durvalumab) | Phase 1/1b | [30] | |
| AZD4635 | NCT02740985 | Advanced cancers | Anti-PDL1 (durvalumab) | Phase 1 | [31] | |
| A2BR | PBF-1129 | NCT03274479 | NSCLC | N/A | Phase 1 | [32] |